ArticleClinical and translational radiation oncology2017
Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients.
Article in Clinical and translational radiation oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gastrointestinal Malignancies and the COVID-19 Pandemic: Evidence-Based Triage to Surgery.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Pooled it
- Microscopic intramural extension of rectal cancer after neoadjuvant chemoradiation: A meta-analysis based on individual patient data.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020Pooled it
- Effect of prolonged interval between neoadjuvant chemoradiotherapy and surgery on pathological and oncological outcomes in locally advanced rectal cancer: a randomized controlled trial.International journal of colorectal disease · 2026Trial
- Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.Radiation oncology (London, England) · 2020Trial
- A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Profiling neoadjuvant therapy response in rectal cancer using meta-analysis of publicly available transcriptomic RNA-seq datasets.Molecular oncology · 2026Article
- Integrated Bioinformatic and Experimental Analysis ofBiomedicines · 2026Article
- Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response.Journal of surgical oncology · 2026Article
- Predictive value of primary gross tumor volume measured by MRI in response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Journal of applied clinical medical physics · 2026Article
- ESTRO consensus guidelines on GTV delineation and dose-escalation in rectal cancer.Clinical and translational radiation oncology · 2026Article
- The Role of MRI in Non-Operative Management of Locally Advanced Rectal Cancer.Journal of gastrointestinal cancer · 2026Review
- Predictive factors of pathologic good response after neoadjuvant chemoradiotherapy for rectal cancer.Discover oncology · 2025Article
- Rectal-RadioSAM: Large model-assisted multi-parametric magnetic resonance imaging pipeline for predicting response to neoadjuvant chemoradiotherapy in rectal cancer without human intervention.Physics and imaging in radiation oncology · 2025Article
- Dose Escalation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Short-Term Efficacy and Toxicity of VMAT-SIB vs. 3D-CRT.Medicina (Kaunas, Lithuania) · 2025Article
- Delayed Surgery after Neoadjuvant Short-course Radiation for Rectal Cancer Improves Pathologic Outcomes without Impacting Survival: A National Cancer Database Analysis.Journal of gastrointestinal cancer · 2024Article
- Advances in MRI-Based Assessment of Rectal Cancer Post-Neoadjuvant Therapy: A Comprehensive Review.Journal of clinical medicine · 2023Review
- A primer on rectal MRI in patients on watch-and-wait treatment for rectal cancer.Abdominal radiology (New York) · 2023Review
- Local Excision Versus Total Mesorectal Excision After Favourable Response to Neoadjuvant Therapy in Low Rectal Cancer: a Multi-centre Experience.Indian journal of surgical oncology · 2023Article
- Restaging rectal cancer following neoadjuvant chemoradiotherapy.World journal of gastrointestinal oncology · 2023Review
- Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) - A multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Study Group.Clinical and translational radiation oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo retrospectively evaluate the difference in terms of pathologic complete response (pCR) according to time elapsed between chemoradiation (CRT) and total mesorectal excision (TME) on a large unselected real-life dataset of locally advanced rectal cancer (LARC) patients.
methodsA multicentre retrospective cohort study of LARC patients from 21 Italian Radiotherapy Institutions was performed. Patients were stratified into 3 different time intervals from CRT. The 1st group included 300 patients who underwent TME within 6 weeks, the 2nd 1598 patients (TME within 7-12 weeks) and the 3rd 196 patients (TME within 13 or more weeks after CRT), respectively.
resultsData on 2094 LARC patients treated between 1997 and 2016 were considered suitable for analysis. Overall, 578 patients had stage II while 1516 had stage III histological proven invasive rectal adenocarcinoma. A CRT schedule of one agent (
conclusionWe confirmed on a population-level that lengthening the interval (>13 weeks) from CRT to surgery improves the pathological response (pCR and pathologic partial response; pPR) in comparison to historic data. Furthermore, radiotherapy dose >5040 cGy and two drugs chemotherapy correlated with pPR rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.